- Watson Pharma $WPI held its 2q2011 earnings conference call 7/26/11 - click here for transcript link.
- WPI was recently announced as the partner for Antares Pharma's Anturol transdermal oxybuntynin gel for overactive bladder (see details on AIS research page) - or click here for press release.
- The deal did not include an upfront, would involve a milestone payment on approval (NDA is pending), and undisclosed royalties. These terms are not as good as hoped - perhaps because of troublesome patents in the space that WPI already had.
- See this blog post for comments made by WPI exec about M&A activity at investor conference shortly before the deal was announced in July 2011.
- Quote from CC (only mention): "And shortly after the close of the quarter, we expanded our brand pipeline through an exclusive licensing agreement with Antares to commercialize their topical oxybutynin gel product in the U.S. and Canada. This licensing agreement is a great example of the ways we will look to supplement our growing brand business portfolio."
- No further details of the licensing deal were reported in the 2q2011 10q's filed by either AIS or WPI. As the deal was closed in 3q2011, the upcoming quarterly reports may have the license agreement in redacted form.
- Note there will be further notes about the Anturol program when I post my notes from the AIS 2q2011 conference call.
RSS Feed
